Analyzing Valeant’s Quarterly Earnings and Estimates

Valeant’s earnings

Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.

Analyzing Valeant’s Quarterly Earnings and Estimates

The above chart compares the non-GAAP EPS for Valeant since the first quarter of 2017 and the estimates for the second quarter.

First-quarter earnings 

Valeant reported a non-GAAP net income of ~$312 million during the first quarter—14% growth compared to ~$273 million during the first quarter of 2017. Also, the non-GAAP EPS was $0.88 during the first quarter—compared to $0.78 during the first quarter of 2017.

Second-quarter earnings and EPS estimates

Wall Street analysts expect an adjusted net income (non-GAAP) of $269 million and an adjusted EPS (non-GAAP) of $0.78 during the second quarter—compared to the adjusted net income of $362 million and the adjusted EPS of $1.03 during the second quarter of 2017.

2018 guidance

Valeant updated its 2018 guidance in May. According to the new guidance, the revenues are expected to be $8.15 billion–$8.35 billion for fiscal 2018. Also, the adjusted EBITDA (non-GAAP) is expected to be $3.15 billion–$3.30 billion for fiscal 2018. However, there weren’t any changes for selling, general, and administrative expenses or research and development expenses for 2018. The expenses are assumed at $2.5 billion and $425 million, respectively.

Notably, the Vanguard FTSE Developed Markets ETF (VEA) holds 0.03% of its total investments in Valeant, 0.4% in Sanofi (SNY), 0.4% in AstraZeneca (AZN), and 0.5% in GlaxoSmithKline (GSK).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!